Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).
Hepatocellular Carcinoma
DRUG: Sintilimab|DRUG: Bevacizumab Biosimilar
Adverse Events (AEs), Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0; Surgical safety including Intraoperative blood loss，PHLF assessed by ISGLS（2012），Postoperative complications evaluated by modified Clavien-Dindo system, Up to 2 years|Events Free Survival (EFS) Assessed by RECIST1.1, Defined as the time from enrollment to disease progression, recurrence or death (whichever occurs first), Up to 2 years
resection rate (R0 resection rate), Defined as the proportion of patients undergoing radical resection to the total subjects (R0 resection rate), Up to 2 years|Pathological response rate, Defined as the proportion of patients who had pathological response., Up to 2 years|Objective response rate (ORR) assessed by RECIST1.1, Defined as the proportion of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR)., Up to 2 years|Recurrence-free survival (RFS) of patients who accepted surgery, Defined as the time from the date of surgery to the date of disease recurrence or death whichever occur first, assessed up to 2 years post-treatment, Up to 2 years|Progression free survival (PFS) assessed by RECIST1.1 of patients who didn't accept surgery, Defined as the time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first., Up to 2 years|Overall survival (OS) of the patients who accepted surgery, Defined as the time from the date of treatment start to the date of death or to the date of last follow-up for patients alive., Up to 2 years|Overall survival (OS) of the patients who didn't accepted surgery, Defined as the time from the date of treatment start to the date of death or to the date of last follow-up for patients alive., Up to 2 years|Overall survival (OS), Defined as the time from the date of treatment start to the date of death or to the date of last follow-up for patients alive, Up to 2 years
This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).